A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Brad S. Kahl, Stephen Spurgeon, Richard R. Furman, Ian W. Flinn, Steven E. Coutre, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert Yu, Wayne R. Godfrey, Nina D. Wagner-Johnston

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase d (PI3Kd), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Patients without DLT and no evidence of disease progression after 48 weeks enrolled in the extension study. Patients had median age of 69 years (range, 52-83) and receivedmedian of 4 prior therapies (1-14); 17 of 40 patients (43%) were refractory to their most recent treatment. Median duration of idelalisib treatment was 3.5 months (range, 0.7-30.7), with 6 (15%) continuing extension treatment. Commongrade ≥3 adverse events (AEs) included (total%/grade ≥3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respiratory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20). ORR was 16 of 40 patients (40%), with CR in 2 of 40 patients (5%). Median DOR was 2.7 months, median PFS was 3.7 months, and 1-year PFS was 22%. These data provide proof of concept that targeting PI3Kd is a viable strategy and worthy of additional study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT00710528.

Original languageEnglish (US)
Pages (from-to)3398-3405
Number of pages8
JournalBlood
Volume123
Issue number22
DOIs
StatePublished - May 29 2014

Fingerprint

Phosphatidylinositol 3-Kinase
Mantle-Cell Lymphoma
Refractory materials
Toxicity
Pharmacodynamics
Pharmacokinetics
Aspartate Aminotransferases
Alanine Transaminase
Disease-Free Survival
Fatigue of materials
Appetite
Therapeutics
Exanthema
Respiratory Tract Infections
Nausea
Fatigue
Disease Progression
idelalisib
Diarrhea
Pneumonia

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kahl, B. S., Spurgeon, S., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., ... Wagner-Johnston, N. D. (2014). A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood, 123(22), 3398-3405. https://doi.org/10.1182/blood-2013-11-537555

A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). / Kahl, Brad S.; Spurgeon, Stephen; Furman, Richard R.; Flinn, Ian W.; Coutre, Steven E.; Brown, Jennifer R.; Benson, Don M.; Byrd, John C.; Peterman, Sissy; Cho, Yoonjin; Yu, Albert; Godfrey, Wayne R.; Wagner-Johnston, Nina D.

In: Blood, Vol. 123, No. 22, 29.05.2014, p. 3398-3405.

Research output: Contribution to journalArticle

Kahl, BS, Spurgeon, S, Furman, RR, Flinn, IW, Coutre, SE, Brown, JR, Benson, DM, Byrd, JC, Peterman, S, Cho, Y, Yu, A, Godfrey, WR & Wagner-Johnston, ND 2014, 'A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)', Blood, vol. 123, no. 22, pp. 3398-3405. https://doi.org/10.1182/blood-2013-11-537555
Kahl, Brad S. ; Spurgeon, Stephen ; Furman, Richard R. ; Flinn, Ian W. ; Coutre, Steven E. ; Brown, Jennifer R. ; Benson, Don M. ; Byrd, John C. ; Peterman, Sissy ; Cho, Yoonjin ; Yu, Albert ; Godfrey, Wayne R. ; Wagner-Johnston, Nina D. / A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). In: Blood. 2014 ; Vol. 123, No. 22. pp. 3398-3405.
@article{72e4832365df4d52b3902adfb64bb614,
title = "A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)",
abstract = "Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase d (PI3Kd), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Patients without DLT and no evidence of disease progression after 48 weeks enrolled in the extension study. Patients had median age of 69 years (range, 52-83) and receivedmedian of 4 prior therapies (1-14); 17 of 40 patients (43{\%}) were refractory to their most recent treatment. Median duration of idelalisib treatment was 3.5 months (range, 0.7-30.7), with 6 (15{\%}) continuing extension treatment. Commongrade ≥3 adverse events (AEs) included (total{\%}/grade ≥3{\%}) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respiratory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20). ORR was 16 of 40 patients (40{\%}), with CR in 2 of 40 patients (5{\%}). Median DOR was 2.7 months, median PFS was 3.7 months, and 1-year PFS was 22{\%}. These data provide proof of concept that targeting PI3Kd is a viable strategy and worthy of additional study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT00710528.",
author = "Kahl, {Brad S.} and Stephen Spurgeon and Furman, {Richard R.} and Flinn, {Ian W.} and Coutre, {Steven E.} and Brown, {Jennifer R.} and Benson, {Don M.} and Byrd, {John C.} and Sissy Peterman and Yoonjin Cho and Albert Yu and Godfrey, {Wayne R.} and Wagner-Johnston, {Nina D.}",
year = "2014",
month = "5",
day = "29",
doi = "10.1182/blood-2013-11-537555",
language = "English (US)",
volume = "123",
pages = "3398--3405",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

AU - Kahl, Brad S.

AU - Spurgeon, Stephen

AU - Furman, Richard R.

AU - Flinn, Ian W.

AU - Coutre, Steven E.

AU - Brown, Jennifer R.

AU - Benson, Don M.

AU - Byrd, John C.

AU - Peterman, Sissy

AU - Cho, Yoonjin

AU - Yu, Albert

AU - Godfrey, Wayne R.

AU - Wagner-Johnston, Nina D.

PY - 2014/5/29

Y1 - 2014/5/29

N2 - Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase d (PI3Kd), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Patients without DLT and no evidence of disease progression after 48 weeks enrolled in the extension study. Patients had median age of 69 years (range, 52-83) and receivedmedian of 4 prior therapies (1-14); 17 of 40 patients (43%) were refractory to their most recent treatment. Median duration of idelalisib treatment was 3.5 months (range, 0.7-30.7), with 6 (15%) continuing extension treatment. Commongrade ≥3 adverse events (AEs) included (total%/grade ≥3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respiratory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20). ORR was 16 of 40 patients (40%), with CR in 2 of 40 patients (5%). Median DOR was 2.7 months, median PFS was 3.7 months, and 1-year PFS was 22%. These data provide proof of concept that targeting PI3Kd is a viable strategy and worthy of additional study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT00710528.

AB - Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase d (PI3Kd), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, overall response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Patients without DLT and no evidence of disease progression after 48 weeks enrolled in the extension study. Patients had median age of 69 years (range, 52-83) and receivedmedian of 4 prior therapies (1-14); 17 of 40 patients (43%) were refractory to their most recent treatment. Median duration of idelalisib treatment was 3.5 months (range, 0.7-30.7), with 6 (15%) continuing extension treatment. Commongrade ≥3 adverse events (AEs) included (total%/grade ≥3%) diarrhea (40/18), nausea (33/5), pyrexia (28/0), fatigue (25/3), rash (23/3), decreased appetite (20/15), upper respiratory infection (20/0), pneumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20). ORR was 16 of 40 patients (40%), with CR in 2 of 40 patients (5%). Median DOR was 2.7 months, median PFS was 3.7 months, and 1-year PFS was 22%. These data provide proof of concept that targeting PI3Kd is a viable strategy and worthy of additional study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT00710528.

UR - http://www.scopus.com/inward/record.url?scp=84901724050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901724050&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-11-537555

DO - 10.1182/blood-2013-11-537555

M3 - Article

VL - 123

SP - 3398

EP - 3405

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -